Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …

This article reviews the small percentage of thyroid tumours that are not classified as classic
papillary thyroid carcinoma, follicular thyroid carcinoma, and medullary thyroid carcinoma. It …

Background Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies,
representing less than 5% of all thyroid carcinomas. Τhe median survival is limited to months …

Background Lenvatinib has been approved by regulatory agencies in Japan, the United
States, and the European Union for treatment of radioiodine-refractory differentiated thyroid …

Apatinib, an inhibitor of vascular endothelial growth factor receptor-2, has been shown to
promote anti-cancer action across a wide range of malignancies, including gastric, lung, and …

Context: Currently there are no efficacious therapies for patients with anaplastic thyroid
carcinoma (ATC) that result in long-term disease stabilization or regression. Objective: We …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were …

Background/Aims: Anaplastic thyroid carcinoma (ATC) is one of the most lethal human
malignancies, and there is no efficient method to slow its process. Apatinib, a novel tyrosine …

Thyroid cancer is the most common endocrine neoplasm accounting for approximately 1,
7% of total cancer diagnoses. The gold standard for evaluation of thyroid nodules is cytology …

Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer, and often
derives from pre-existing well-differentiated tumors. Despite a relatively low prevalence, it …